Upadacitinib in a phase 2 study of adults with non-segmental vitiligo: Thierry Passeron

Touch Medical Media coverage of data presented at EADV 2023:

The phase 2b study evaluating upadacitinib (RINVOQ®) in adults with non-segmental vitiligo achieved the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index, with no new safety signals identified. touchDERMATOLOGY caught up with Prof. Thierry Passeron (University Hospital of Nice, Nice, France) to discuss the impact of JAK inhibitors on the treatment landscape for vitiligo and the clinical significance of the phase 2 efficacy and safety findings.

This information is provided solely by Touch Medical Media and is independent of any sponsorship or affiliation with the European Academy of Dermatology & Venereology (EADV).

The abstract ‘Efficacy and Safety of Upadacitinib in a Phase 2 Randomized, Double-Blind, Dose-Ranging Study of Adults With Extensive Non-Segmental Vitiligo.’ (Abstract N°: 2582) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress.

Questions

1. What impact have JAK inhibitors already had on the treatment landscape for vitiligo? (0:11)
2. What was the rationale for investigating upadacitinib in this indication, and who is likely to benefit most from this treatment? (0:30)
3. What were the aims, design, and eligibility criteria of your phase 2 study? (1:05)
4. What were the efficacy and safety findings of the study? (1:30)
5. What is the potential clinical significance of these findings? (2:16)

Disclosures: Thierry Passeron has been a consultant for Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, UCB pharma; received grant/research support from Abbvie, Almirall, BMS, Celgene, Incyte, Isocell, LEO Pharma, Lilly; and has recieved honorarium from Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, UCB pharma.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch.

Filmed in coverage of the EADV Annual Meeting.

This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Click here for more content on vitiligo and pigmentation disorders & for further EADV 2023 highlights visit here.